Hair relaxer cancer lawsuit MDL 3060: how the chemical straightener litigation actually works

The hair relaxer cancer litigation has become one of the largest and fastest-growing mass torts in the United States, with MDL 3060 (In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation) consolidating more than 10,000 federal lawsuits as of mid-2026. The case theory alleges that chemical hair straightening products manufactured by L'Oréal, Revlon, Namaste Laboratories, Strength of Nature, Softsheen-Carson, and other major cosmetics companies contain endocrine-disrupting chemicals that, with chronic use, cause uterine cancer, endometrial cancer, ovarian cancer, and related reproductive system conditions. The plaintiffs are disproportionately Black women, who use these products at much higher rates than other demographic groups; the products were specifically marketed to and developed for Black hair textures.

The litigation traces to October 2022 publication of the National Institutes of Health Sister Study findings showing that women who used hair straighteners more than four times per year had 2.55 times the risk of developing uterine cancer compared to non-users. The study, which tracked 33,497 women over approximately 11 years, provided the scientific foundation for the litigation. The first lawsuits were filed in late 2022, and the Judicial Panel on Multidistrict Litigation centralized federal cases in MDL 3060 in February 2023 in the Northern District of Illinois before Judge Mary M. Rowland. The case count grew rapidly through 2023, 2024, and 2025, doubling multiple times as plaintiffs' counsel screened and signed up additional clients.

The procedural posture in mid-2026 reflects active pre-trial development. Judge Rowland held Science Day on January 8, 2026 to educate the court on the scientific evidence linking chemical straighteners to hormone-related cancers. The bellwether trial pool was narrowed from 40 initial selections (20 from each side) to 32 cases, with three bellwether cases picked by early April 2026. Fact discovery for the first bellwether group runs through mid-March 2026, with general causation evidence due by March 2026. Bellwether trials are expected in late 2026 or early 2027. State court parallel litigation continues, with Pennsylvania state court cases consolidated in April 2025.

This is the science behind the hair relaxer-cancer theory, the procedural history of MDL 3060, the eligibility framework for filing claims, the bellwether trial framework, and the strategic considerations for both pending and prospective plaintiffs.

What chemicals in hair relaxers are linked to cancer?

Chemical hair relaxers contain or release endocrine-disrupting substances, including formaldehyde (classified as a known human carcinogen by IARC), phthalates, parabens, and bisphenol A. Chronic scalp absorption over decades of regular use creates cumulative body burdens of these chemicals, which plaintiffs allege cause uterine cancer, ovarian cancer, endometrial cancer, and related reproductive conditions.

Chemical hair relaxers work by breaking the disulfide bonds in hair to permanently straighten it. The process requires harsh chemicals applied directly to the scalp, where they can be absorbed through the skin and through the small burns and irritations the chemicals typically cause. The products contain or release various chemicals identified as endocrine disruptors:

Formaldehyde and formaldehyde-releasing chemicals. Many hair relaxers contain or release formaldehyde during application. Formaldehyde is classified as a known human carcinogen by the International Agency for Research on Cancer (IARC).

Phthalates. Multiple phthalate compounds appear in hair relaxers as plasticizers and fragrance components. Phthalates are well-documented endocrine disruptors that interfere with hormone function.

Parabens. Used as preservatives in many cosmetic products including hair relaxers. Parabens have weak estrogenic activity and have been associated with breast cancer in some studies.

Di-2-ethylhexyl phthalate (DEHP). A specific phthalate compound that's been particularly implicated in endocrine disruption research.

Bisphenol A (BPA) and similar compounds. Used in some product packaging and formulations. Known endocrine disruptors.

Heavy metals. Some hair relaxers contain trace amounts of heavy metals as contaminants or active ingredients. Lead and other metals can have various toxic effects.

The chronic exposure pattern is the key concern. Users typically apply hair relaxers every 6-8 weeks for decades. Cumulative chemical exposure over decades of use produces substantial total body burden of endocrine-disrupting chemicals. The exposure occurs through scalp absorption (the chemicals contact skin during application) and through inhalation (volatile compounds are released during the heat and chemical reactions of the process).

The cancers alleged to be caused by chronic hair relaxer use:

What is the procedural history of MDL 3060?

MDL 3060 was created in February 2023 when the JPML centralized federal hair relaxer lawsuits in the Northern District of Illinois before Judge Mary M. Rowland. The case count has grown to approximately 10,000 to 11,400 as of mid-2026. Science Day was held January 8, 2026, three bellwether cases were selected by early April 2026, and the first bellwether trials are expected in late 2026 or early 2027.

The litigation has developed rapidly:

October 2022. NIH Sister Study published in the Journal of the National Cancer Institute, providing the scientific foundation for the litigation.

Late 2022. First hair relaxer cancer lawsuits filed. Early cases focused primarily on uterine cancer claims.

February 2023. JPML centralized federal cases in MDL 3060, Northern District of Illinois, Judge Mary M. Rowland.

2023. Case count grew from initial filings to over 1,000 cases by year end. Discovery began with initial document production from defendants.

2024. Case count continued growing. Bellwether selection framework developed. Plaintiffs' Steering Committee organized and structured for coordinated representation.

January 10, 2025. Joint Status Report filed proposing bellwether trial process. Lawyers on each side could select 20 lawsuits for the bellwether pool, with selections due by April 30, 2025.

April 30, 2025. Bellwether pool selections submitted (40 total: 20 from each side).

April 2025. Pennsylvania state court cases consolidated, creating parallel state court track.

Throughout 2025. Bellwether pool narrowed from 40 to 32 cases. Discovery on bellwether cases proceeded.

Pl Steering Committee request. The PSC requested 11% of total gross settlement or judgment to be reserved for plaintiff benefit fund (8% for common benefit work, 3% for expenses).

January 8, 2026. Science Day held. Expert witnesses from both sides presented scientific information on the alleged links between chemical hair straighteners and hormone-related cancers.

February 5, 2026. Judge Rowland set new bellwether preparation deadlines. Court planned to pick three bellwether cases by early April 2026.

Early April 2026. Three bellwether cases selected. Fact discovery for the first bellwether group set to finish by mid-March 2026.

Late 2026 / Early 2027. First bellwether trials expected.

The case count as of mid-2026 was approximately 10,000-11,400 (numbers vary by reporting source and date). The MDL continues to grow at approximately 100-300 new cases per month.

Who qualifies to file a hair relaxer cancer lawsuit?

To qualify, a claimant must have used chemical hair relaxers regularly (at least four times per year for multiple years), received a documented diagnosis of a qualifying condition such as uterine, endometrial, or ovarian cancer, and be able to identify specific products used. The claim must also fall within the applicable state statute of limitations.

The eligibility framework for filing hair relaxer cancer claims:

Regular use of chemical hair relaxers. The claimant used chemical hair relaxers regularly over an extended period. "Regular use" typically means at least 4 times per year (the threshold from the NIH Sister Study) for multiple years. Casual or infrequent use doesn't fit the case theory.

Documented qualifying diagnosis. The claimant developed:

• Uterine cancer (the strongest typical case)
• Endometrial cancer
• Ovarian cancer
• Endometriosis (in some firms' eligibility frameworks)
• Uterine fibroids (in some firms' eligibility frameworks)
• Breast cancer (in some firms' eligibility frameworks, with stronger evidence required)

Product identification. Records or recall of specific products used. The major defendants include L'Oréal (multiple product lines), Revlon (Revlon Realistic), Namaste Laboratories (Dabur, Just for Me, Olive Oil Relaxer), Strength of Nature (Just for Me, Profectiv), Softsheen-Carson (Optimum Care, Dark and Lovely), and other manufacturers.

Temporal proximity. The cancer or condition was diagnosed within a reasonable time frame after substantial exposure. Cancer development typically requires years of cumulative exposure; the latency period for endocrine-driven cancers is typically decades.

No significant alternative causation. Cases involving strong alternative causes for the specific cancer face more difficult analysis. The plaintiff doesn't need to show hair relaxer use was the sole cause, but the case is stronger when alternative causes are less prominent.

Statute of limitations compliance. State-specific limitations periods apply, typically 2-3 years from diagnosis or 1-4 years from when the connection between the cancer and hair relaxer use was known or should have been known.

The strongest typical case profile:

A Black woman in her 30s-60s who used chemical hair relaxers from teenage years through her 30s-40s (or longer), developed uterine cancer requiring hysterectomy and additional treatment, with documented product use records and medical records establishing both the exposure history and the cancer diagnosis.

How does the bellwether trial process work in MDL 3060?

The bellwether framework begins with each side selecting 20 cases (40 total), narrowed by the court to 32, then to three cases chosen by early April 2026 for the first trial round. Only uterine, endometrial, or ovarian cancer cases are eligible for the bellwether pool.

The bellwether process is structured to test the litigation:

Initial selection. Each side selected 20 cases for the bellwether pool by April 30, 2025 (40 total).

Narrowing to 32 cases. The court narrowed the pool to 32 cases over the following months. Selection considered case strength, representativeness of the broader plaintiff population, and procedural manageability.

Eligibility limitation. Only cases involving uterine, endometrial, or ovarian cancer are eligible for the bellwether pool. Cases involving endometriosis, fibroids, or other non-cancer conditions aren't represented in the bellwether trial framework.

Three early bellwethers. Three bellwether cases were picked by early April 2026 for the first round of trial preparation.

Substitution provision. When a bellwether discovery case settles before trial selection, the court has granted plaintiffs authority to select a replacement case unilaterally. This is a standard MDL provision that prevents defendants from settling out the strongest plaintiff cases.

Expected trial timing. First bellwether trials expected late 2026 or early 2027. Multiple sources suggest 2027 as the more realistic timeline given typical MDL development delays.

The bellwether trial outcomes will substantially affect global settlement discussions. Substantial plaintiff verdicts in the bellwether trials would increase pressure on defendants to settle remaining cases. Defense verdicts would reduce settlement leverage and may extend litigation.

What are the expected hair relaxer lawsuit settlement amounts?

The total potential value of the litigation is estimated in the multiple billions of dollars, with actual amounts depending on bellwether trial outcomes.

Tiered compensation likely. Based on cancer type, severity, treatment intensity, and age at diagnosis. Uterine and ovarian cancer cases typically project to higher tiers than less-severe conditions.

State court v. federal MDL. State court cases (particularly Pennsylvania consolidated cases and Illinois state court cases) may produce different outcomes from federal MDL cases. Some state court cases may reach trial before federal bellwether trials.

The estimated total potential value of the litigation, based on case volume and per-case projections, is in the multiple billions of dollars.

How does the hair relaxer MDL compare to other mass torts?

The hair relaxer litigation is distinguished by strong NIH-backed general causation evidence, a concrete bellwether schedule, and a plaintiff population disproportionately composed of Black women. Compared to mass torts like Zantac (dismissed on Daubert grounds) and Tylenol autism (also dismissed), hair relaxer's published Sister Study data provides a more robust scientific foundation that is less vulnerable to expert exclusion.

The hair relaxer litigation has distinctive features:

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. Hair relaxer represents one of the major active mass torts with substantial expected resolution value.

What are the strategic considerations for hair relaxer plaintiffs?

Potential plaintiffs should file promptly to avoid statute of limitations issues, engage experienced mass tort counsel (most work on contingency at 30-40% of recovery), thoroughly document their product exposure history and medical records, and plan for a 3-5 year resolution timeline. Wrongful death claims are available for estates of deceased plaintiffs.

For potential plaintiffs:

Don't delay filing. Statute of limitations issues are significant in cancer cases. The discovery rule provides some flexibility (tolling limitations until the connection between hair relaxer use and cancer was known or should have been known), but the rule has limits. Earlier filing preserves claim viability.

Engage experienced mass tort counsel. Hair relaxer cases require specialized knowledge. Most plaintiffs' firms handling these cases work on contingency basis (typically 30-40% of recovery). Free consultations are standard.

Document exposure thoroughly. Product purchase records, photographs of hair styles, records of hair appointments (for salon-applied relaxers), insurance records that may reflect related health concerns, and similar documentation. Friends and family members who can verify exposure history through declarations or testimony.

Obtain comprehensive medical records. The case strength depends substantially on medical documentation. Pathology reports establishing the specific cancer type. Treatment records showing the severity and intensity of treatment. Records of complications and ongoing health effects. Records of fertility implications for women requiring hysterectomy or oophorectomy.

Be realistic about timeline. Even strong cases will take 2-4 years to resolve. Bellwether trials in late 2026 / 2027 will affect settlement timing. Most plaintiffs should plan for 3-5 year resolution timelines.

Consider state court v. MDL strategy. Cases can typically be filed in federal MDL or state court depending on jurisdiction. State court cases may proceed on different timelines than federal MDL. The strategic choice depends on case-specific factors and the law firm's overall approach.

Wrongful death framework. Estates of deceased plaintiffs can pursue wrongful death claims with separate value calculations including economic damages (lost earnings) and family member damages.

Coordinate with treating physicians. Medical records establishing the connection between hair relaxer exposure and cancer are critical. Treating physicians should be aware of the litigation framework and the relevance of their documentation.

Statute of limitations is critical. Time-barred claims aren't revived regardless of merit. Cases involving very old cancer diagnoses with long delays in connecting exposure to outcome may face limitations issues. Early consultation with counsel preserves claims that might otherwise be lost.

The hair relaxer cancer litigation represents substantial accountability for cosmetics manufacturers who marketed potentially carcinogenic products primarily to Black women without adequate warnings about cancer risks. For plaintiffs whose cancer diagnoses are connected to their hair relaxer use history, the framework provides meaningful paths to compensation. The bellwether trial outcomes in late 2026 or 2027 will determine the broader settlement framework, with substantial implications for the value of remaining cases. For potential plaintiffs, engagement with experienced counsel, thorough documentation, and timely filing within applicable limitations periods are the procedural steps that preserve eligibility for participation in whatever resolution framework ultimately emerges from the litigation. The science underlying the claims is strong, the procedural framework is developing constructively, and the eventual outcomes should provide meaningful recovery for qualifying plaintiffs.

This post is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for guidance on your specific situation.